Skip to main content
. 2023 Mar 25;27(3):102759. doi: 10.1016/j.bjid.2023.102759

Table 3.

. In vitro susceptibility of P. aeruginsoa collected in six Latin American countriesa divided into two 3-year time periods 2015‒2017 and 2018‒2020.

Collection years (n) Compound Range MIC50 MIC90 CLSI Interpretationb
(µg/mL) %S %I %R
2015‒2017 (2054) Amikacin ≤ 0.25 – > 32 4 > 32 82.0 3.4 14.6
Aztreonam 0.06 – > 128 8 64 58.9 13.9 27.2
Cefepime 0.5 – > 16 4 > 16 72.5 10.7 16.8
Ceftazidime 0.06 – > 128 4 128 69.2 4.7 26.1
Ceftazidime-avibactam 0.03 – > 128 2 32 86.6 NA 13.4
Colistin ≤ 0.06 – > 8 1 2 NA 99.3 0.7
Imipenem 0.12 – > 8 2 > 8 59.9 5.8 34.2
Levofloxacin 0.015 – > 8 1 > 8 59.0 7.5 33.5
Meropenem ≤ 0.004 – > 8 1 > 8 65.0 5.7 29.3
Piperacillin Tazobactam ≤ 0.25 – > 128 8 > 128 66.2 14.4 19.4
2018‒2020 (2560) Amikacin ≤ 0.25 – > 64 4 64 81.1 3.1 15.8
Aztreonam 0.12 – > 128 8 64 62.3 14.1 23.6
Cefepime ≤ 0.12 – > 32 4 > 32 71.3 10.7 17.9
Ceftazidime 0.25 – > 128 4 64 70.9 4.4 24.6
Ceftazidime-avibactam ≤ 0.03 – > 128 2 32 85.3 NA 14.7
Colistin ≤ 0.12 – > 8 1 2 NA 99.8 0.2
Imipenem 0.12 – > 8 2 >8 56.7 8.9 34.4
Levofloxacin ≤ 0.25 – > 8 0.5 >8 62.2 8.1 29.7
Meropenem ≤ 0.06 – > 16 1 >16 65.0 6.4 28.6
Piperacillin Tazobactam ≤ 0.12 – > 64 8 >64 67.5 14.3 18.3
a

Countries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.

b

S, susceptible; I, intermediate; R, resistant.